Ken Griffin Novo Nordisk A S Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$119.07 - $145.42 $52.4 Million - $64 Million	-440,000 Reduced 24.68%	1,342,800 $160 Million
Q2 2024 Aug 14, 2024	SELL	$122.71 - $146.91 $24.6 Million - $29.4 Million	-200,200 Reduced 10.1%	1,782,800 $254 Million
Q1 2024 May 15, 2024	BUY	$102.11 - $135.92 $84 Million - $112 Million	822,600 Added 70.89%	1,983,000 $255 Million
Q4 2023 Feb 14, 2024	BUY	$87.78 - $105.45 $4.75 Million - $5.7 Million	54,100 Added 4.89%	1,160,400 $120 Million
Q3 2023 Nov 14, 2023	BUY	$90.94 - $199.54 $58.1 Million - $128 Million	639,300 Added 136.9%	1,106,300 $101 Million
Q2 2023 Aug 14, 2023	BUY	$155.98 - $172.65 $15.9 Million - $17.6 Million	101,900 Added 27.91%	467,000 $75.6 Million
Q1 2023 May 15, 2023	BUY	$132.34 - $159.14 $14.8 Million - $17.8 Million	111,900 Added 44.19%	365,100 $58.1 Million
Q4 2022 Feb 14, 2023	SELL	$102.55 - $135.33 $9.36 Million - $12.4 Million	-91,300 Reduced 26.5%	253,200 $34.3 Million
Q3 2022 Nov 14, 2022	BUY	$95.28 - $116.93 $15.5 Million - $19 Million	162,900 Added 89.7%	344,500 $34.3 Million

1,955

320M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $240B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.